Microbial Qualification as Mission Value

The business case for microbial assurance begins with qualification before efficacy. A configuration that fails early under declared rules can still serve the larger effort by preventing a less mature design from advancing. Claims about return, customer demand, procurement, adoption, or mission savings require separate supporting evidence.

Mission value has a defined meaning here: evidence for a continue, redesign, or stop decision. Within a bounded campaign, qualification can expose identity mismatch, viability loss, functional drift, incomplete traceability, resource burden, contamination, and failure behavior. Its service is a clearer decision, not a guarantee of a favorable result or customer action.

The frozen evidence package contains 114 source rows resolving to 72 analysable studies from 2,434 unique records, and it supports that boundary. No reviewed record measures probiotic viability after actual-flight storage. Among 22 retrieved human-tier full texts, zero provides a functional outcome with a statistic. All three microbiome-manipulation studies with host outcomes are T4 simulation designs. Across the 72 analysed records, zero provides quantified mass, volume, shelf life, power, or crew-time values for countermeasures (Gastronaut 2026 synthesis).

NASA therefore has a qualification-design question before an efficacy conclusion. Investors have a capital-staging question before financial valuation. One evidence package serves both decisions, while preserving the different duties attached to each.

What the record requires qualification to answer

Two T4 in vitro studies define the qualification questions. Shao et al. report that simulated exposure altered characteristics of Lactobacillus acidophilus. Afsharian, Salavatifar, and Khosravi Darani report altered heavy-metal bioremoval efficiency. The latter result concerns an environmental function, not clinical probiotic performance. Keeping that distinction intact protects the value of both findings.

Neither record answers what happens during actual-flight storage. The findings establish the need to measure identity, viability, and function retention separately. An organism can remain identifiable while losing viability; a viable organism can retain a cell count while changing a relevant function. The meaning of any shift depends on the intended use and declared acceptance range, which later reviewers must be able to recover from the record.

The synthesis adds two boundaries. Human-tier functional statistics are absent from the 22 retrieved full texts, and causal manipulation with host outcomes stops at T4. Neither gap proves that a countermeasure fails. Together, they prevent a qualification result from being presented as a human or flight efficacy result.

One reporting feature also belongs in the qualification record. Of 24 countermeasure records, 13 state a direction and all 13 are beneficial; 11 state no direction. The positive-only directional pattern may reflect effective interventions, selective reporting, related-study clusters, or other evidence-production effects. Publication bias remains plausible, not proven. A qualification plan that retains unfavorable and null results gives the next decision a fuller inheritance than positive-only reporting can provide.

The qualification contract

NASA can organize microbial assurance around eight gates. Together, they form a qualification contract with a declared method, threshold, deviation rule, and disposition for each question. The contract gives every result, favorable or otherwise, a defined place in the continuing record.

1. Identity. Confirm strain, line, lot, source, and preparation using a declared identity assay. An identity mismatch triggers quarantine and investigation.
2. Storage viability. Measure viability at defined intervals under controlled storage conditions. Report units, detection limits, controls, replicate structure, and uncertainty.
3. Function retention. Measure the function relevant to the proposed use. Do not substitute identity, abundance, or viability for a direct functional assay.
4. Traceability. Link every result to sample custody, environmental history, instrument, operator, processing step, and analysis version.
5. Contamination response. Define detection, confirmation, isolation, cleaning, retest, disposition, and reporting before a campaign begins.
6. Human relevance. State exactly how the chosen endpoint relates to a human question and where the model boundary prevents transfer. Human relevance is a gate for further study, not a clinical conclusion.
7. Resource accounting. Measure mass, volume, shelf life, power, and crew time for the tested configuration. The synthesis provides no quantified values for these countermeasure burdens, so estimates remain separate from corpus findings.
8. Failure reporting. Preserve null, unfavorable, invalid, and terminated results. Report protocol deviations and related-study clusters alongside favorable findings.

Passing one gate does not imply passage through the others. A viable organism may fail function retention. A successful assay may sit within an incomplete custody record. A biologically interesting result may carry an operational burden that has not been measured. Separate dispositions keep the later decision reviewable and the evidence chain honest.

How a bounded campaign earns its next step

Three thresholds make the gates actionable. Acceptance defines the result needed to continue. Redesign identifies a correctable shortfall, such as assay variability, container interaction, or storage-condition drift. Stop identifies a result that ends the current configuration, such as identity failure, unrecoverable custody loss, confirmed contamination, or predefined functional loss.

The thresholds are set before testing and apply to favorable and unfavorable outcomes. Independent assay review can assess whether controls, replicate structure, and measurement uncertainty support each disposition. The campaign record retains raw observations, deviations, exclusions, and the rationale for every continue, redesign, or stop decision, preserving continuity from test to judgment.

Qualification retains decision value when a configuration does not pass. A negative result can prevent escalation of an unready design; a variable result can identify the next assay or engineering question. A successful bounded result can justify a higher-tier test. Each outcome serves the next decision, and none establishes customer demand or financial return.

NASA decision

NASA can select one live-organism storage and function-retention case, then apply all eight gates in a ground campaign. The protocol defines the organism, intended function, storage interval, environmental conditions, reference controls, sample schedule, resource-accounting method, and decision thresholds. NASA’s responsibility is to decide whether the resulting evidence package supports continuation under its own readiness criteria.

NASA’s deliverable is an evidence package, not a promotional claim. It shows which gates passed, which did not, what remains unknown, and whether the appropriate disposition is continue, redesign, or stop. A later analog or flight study follows only if that evidence supports it under separate readiness criteria.

Investor decision

Investors can bound early capital through independent qualification outcomes. Funding stages can follow assay validation, storage-viability repeatability, function-retention repeatability, traceability completeness, contamination-response demonstration, and resource measurement. Their responsibility is to decide whether a completed technical gate justifies the next tranche, separate from NASA’s program decision.

Those milestones carry no efficacy or market premium. They show whether a test system can answer a declared question, not adoption, demand, revenue, or return. An unfavorable outcome has diligence value when it supports a clear redesign or stop decision and keeps later capital from inheriting an unresolved configuration.

What ORCA can offer for qualification review

Gastronaut is developing ORCA as a 2.0 m diameter standalone modular cultivation enclosure. It is approximately TRL 3 to 4, remains at the ground stage, and has zero flight and lunar cycles. The proposed 0.1 g to 1.0 g research range and nominal 0.5 g to 0.65 g operation are design objectives, not demonstrated performance. The present qualification case is therefore a ground campaign, not a claim to higher-tier readiness.

Gastronaut can offer NASA a proposed data dictionary, readiness assessment, resource-accounting template, ground-validation plan, and ORCA operating-history structure. These company materials are not NASA-validated assets. In a bounded campaign, they could preserve test conditions, samples, assays, deviations, resource observations, and dispositions against the qualification contract.

Gastronaut maintains an internal record of 1,042 ground growth cycles over 18 to 24 months. That history can be structured for review as operating provenance. It does not substitute for flight, lunar, variable-gravity, reliability, biological-efficacy, microbiome, clinical, food-safety, or edited-line evidence. Those categories remain separately unproven.

ORCA has no regulatory or flight-readiness claim from the microbiome evidence described here. This proposed package does not establish efficacy, customer demand, financial value, or mission savings.

Limitations

All corpus counts in this report come from the frozen synthesis of 114 source rows and 72 analysable studies. A later extraction contains 118 source rows and 75 candidate inclusions but remains unreconciled, so the denominators are not combined. The retrieved 22 human-tier full texts do not represent every possible source. The cited T4 studies define test questions within their models; they do not establish actual-flight storage behavior.

Constructive engagement request

Gastronaut proposes a joint scoping session to select one live-organism storage and function-retention case. Before testing, NASA or designated independent reviewers would help declare acceptance, redesign, and stop thresholds. Gastronaut would then map the proposed data dictionary, provenance record, resource template, and fault dispositions to the case. The result would be a bounded ground-validation plan for NASA’s continue, redesign, or stop decision, with the completed gates carried forward for investor diligence and capital staging.

References

Gastronaut. Gut Microbiome and Immune Function: Frozen Evidence Synthesis. Evidence version frozen 21 Aug. 2026. Research synthesis.

Afsharian, S., M. Salavatifar, and K. Khosravi Darani. “Impact of Simulated Microgravity on Bioremoval of Heavy Metals by Lactobacillus acidophilus ATCC 4356 from Water.” Heliyon, https://doi.org/10.1016/j.heliyon.2022.e12307.

Shao, D., et al. “Simulated Microgravity Affects Some Biological Characteristics of Lactobacillus acidophilus.” Applied Microbiology and Biotechnology, 2017, https://doi.org/10.1007/s00253-016-8059-6.